Clinuvel Pharmaceuticals Ltd. plans to appeal the U.K.'s decision to not grant reimbursement for its skin disease drug, Scenesse.
The U.K.'s National Institute for Health and Care Excellence maintained its position against granting the drug reimbursement under the national health service, following an initial rejection in December 2017.
The final recommendation by NICE's Highly Specialised Technologies Evaluation Committee maintained that Scenesse, or afamelanotide, did not meet its health economic criteria for reimbursement.
The Australian biopharmaceutical company focuses on developing treatments for patients with a range of severe genetic and skin disorders.
